Skip to main content

“The remarkable growth reported in 2017 was a direct result of our strategic decisions to reacquire the commercial rights to RUCONEST® in North America and implement direct marketing in the major Western European markets.”

- Sijmen de Vries, Pharming’s CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline